Exelixis (EXEL) shares were up more than 3% in Friday afternoon trading after BMO Capital initiated the stock coverage at outperform and set the price...
Exelixis (EXEL) has an average rating of outperform and price targets ranging from $18 to $35, according to analysts polled by Capital IQ. (MT Newswires...
Exelixis (EXEL) said Tuesday it has initiated a phase 3 trial evaluating its XL092 treatment in combination with either atezolizumab or regorafenib in...
Exelixis (EXEL) said Wednesday that it entered an option and license agreement with Sweden's BioInvent International AB to discover new antibodies for...
| Address | 1851 Harbor Bay Parkway Alameda, California 94502 |
| Phone | +1.650.837.7000 |
| Number of Employees | 484 |
| Recent SEC Filing | 06/01/2022 4 |
| President, Chief Executive Officer & Director | Michael M. Morrissey |
| Executive Vice President-Business Operations | Dana T. Aftab |
| Chief Financial Officer & Executive Vice President | Christopher J. Senner |
| Chief Scientific Officer & EVP-Scientific Strategy | Peter Lamb |
| Price Open | $20.70 |
| Previous Close | $20.79 |
| 52 Week Range | $15.50 - 23.40 |
| Market Capitalization | $6.7 B |
| Shares Outstanding | 320.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 24.15 |
| Earnings per Share | $0.92 |
| Beta vs. S&P 500 | N/A |
| Revenue | $845.7 M |
| Net Profit Margin | 19.60% |
| Return on Equity | 13.77% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
